Latest News-Innovent Biologics,Inc Mediaroom_Page

Innovent Receives NMPA Breakthrough Designation for IBI351 (KRASG12C Inhibitor) as Monotherapy for Previously Treated Advanced Colorectal Carcinoma

ROCKVILLE, Md. and SUZHOU, China, May 15, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent"...

2023-05-15 08:00 4347

Innovent Announces Phase 2 Clinical Study of Higher dose 9 mg Mazdutide (IBI362) in Chinese Adults with Obesity Achieved the 24-Week Primary Endpoint

ROCKVILLIE, Md. and SUZHOU, China, May 11, 2023 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent)...

2023-05-11 08:45 5513

The China NMPA Approves TYVYT® (sintilimab injection) in Combination with Bevacizumab and Chemotherapy in Patients with EGFR-mutated Non-squamous NSCLC who Progressed after EGFR-TKI Therapy

ROCKVILLIE, Md. and SUZHOU, China, May 10, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent...

2023-05-10 08:00 5392

Innovent Announces First Participant Dosed in Phase 3 Study (RESTORE) of IBI311 (Anti-IGF-1R Monoclonal Antibody) in Patients with Thyroid Eye Disease

ROCKVILLE, MD. and SUZHOU, China, May 8, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent")...

2023-05-08 08:00 4658

Innovent Updates the Results from the ORIENT-31 Study of Sintilimab Plus Chemotherapy With or Without Bevacizumab in Patients with EGFR-TKI failed EGFR-mutated Non-Squamous Non-Small Cell Lung Cancer in the Lancet Respiratory Medicine

ROCKVILLE, Md. and SUZHOU, China, May 8, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent")...

2023-05-08 08:00 4803

Innovent Announces Overall Survival Results of Phase 2 Study of Pemazyre® (pemigatinib) in Chinese Patients with Advanced Cholangiocarcinoma Presented at AACR Annual Meeting 2023

ROCKVILLE, Md. and SUZHOU, China, April 19, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innoven...

2023-04-20 08:00 2258

Innovent Announces Overall Survival Results of Phase 2 Study of Pemazyre® (pemigatinib) in Chinese Patients with Advanced Cholangiocarcinoma Presented at AACR Annual Meeting 2023

ROCKVILLE, Md. and SUZHOU, China, April 20, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innoven...

2023-04-20 08:00 4674

Innovent Releases Final Analysis Results of ORIENT-16: the Phase 3 Study of Sintilimab in Combination with Chemotherapy for the First-Line Treatment of Gastric Cancer at the AACR Annual Meeting 2023

ROCKVILLE, Md. and SUZHOU, China, April 18, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innoven...

2023-04-18 08:00 3346

Innovent Announces Updated Data of Phase 1 Clinical Trial for IBI351 (KRAS[G12C] Inhibitor) as Monotherapy for Solid Tumors at the AACR Annual Meeting 2023

ROCKVILLE, Md. and SUZHOU, China, April 18, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innove...

2023-04-18 08:00 3507

Innovent Releases Final Analysis Results of ORIENT-16: the Phase 3 Study of Sintilimab in Combination with Chemotherapy for the First-Line Treatment of Gastric Cancer at the AACR Annual Meeting 2023

ROCKVILLE, Md. and SUZHOU, China, April 17, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innoven...

2023-04-18 08:00 2554

Innovent Releases Final Analysis Results of ORIENT-15: the Phase 3 Study of Sintilimab plus Chemotherapy for the First-Line Treatment of Esophageal Squamous Cell Carcinoma at the AACR Annual Meeting 2023

ROCKVILLE, Md. and SUZHOU, China, April 17, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innoven...

2023-04-17 08:33 4020

Innovent Releases Final Analysis Results of ORIENT-15: the Phase 3 Study of Sintilimab plus Chemotherapy for the First-Line Treatment of Esophageal Squamous Cell Carcinoma at the AACR Annual Meeting 2023

ROCKVILLE, Md. and SUZHOU, China, April 16, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innoven...

2023-04-17 08:20 3427

Innovent Announces 2022 Annual Results and Business Updates

Building an Innovative Biopharmaceutical Company with Sustainable Growth and Comprehensive Capabili...

2023-03-29 08:00 4807

Innovent Announces Clinical Data of Multiple Trials Will be Presented at the AACR Annual Meeting 2023

ROCKVILLE, Md. and SUZHOU, China, March 21, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innove...

2023-03-21 08:00 4319

Innovent Announces First Participant Dosed in Phase 1 Clinical Study of IBI333 (VEGF-A/VEGF-C Bispecific Fusion Protein) in Patients with Neovascular Age-related Macular Degeneration

ROCKVILLE, Md. and SUZHOU, China, Feb. 28, 2023 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent)...

2023-02-28 08:00 4501

Innovent Announces First Patient Dosed in a Phase 3 Clinical Trial (CLEAR) of Picankibart (Anti-IL23p19 Monoclonal Antibody) in Patients with Moderate-to-Severe Plaque Psoriasis

ROCKVILLE, Md. and SUZHOU, China, Feb. 16, 2023 /PRNewswire/ -- Innovent Biologics, Group. ("Innove...

2023-02-16 08:00 4213

Innovent Announces First Participant Dosed in Phase 2 Study of IBI311 (Anti-IGF-1R Monoclonal Antibody) in Patients with Thyroid Associated Ophthalmopathy

ROCKVILLE, Md. and SUZHOU, China, Feb. 15, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent...

2023-02-15 08:00 4698

Innovent Announces Inclusion in the China National Reimbursement Drug List (NRDL) of TYVYT in Two New Indications, Olverembatinib for the First Listing, BYVASDA, HALPRYZA and SULINNO in Multiple New Indications

ROCKVILLE, Md. and SUZHOU, China, Jan. 18, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent...

2023-01-18 21:34 3784

Innovent Announces First Participant Dosed in a Phase 3 Clinical Study (DREAMS-2) of Mazdutide (IBI362) in Chinese Patients with Type 2 Diabetes

ROCKVILLE, Md. and SUZHOU, China, Jan. 11, 2023 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent)...

2023-01-11 00:00 3878

Innovent Announces First Participant Dosed in a Phase 3 Clinical Study (DREAMS-1) of Mazdutide (IBI362) in Chinese Patients with Type 2 Diabetes

ROCKVILLE, Md. and SUZHOU, China, Jan. 10, 2023 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent)...

2023-01-10 00:00 3902